UBS
UBS Initiates Coverage of Myriad Genetics With Neutral Rating
Analysts noted that while continued double-digit growth appears unsustainable in the near term, risks related to UnitedHealthcare's decision on pharmacogenetic testing appear limited.
UBS Initiates Coverage of Veracyte With Buy Rating
Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.
Top Five Articles on 360Dx Last Week: QuidelOrtho's Plans; Sekisui's EUAs for COVID Tests; More
Last week, readers were most interested in an update by QuidelOrtho management on the direction of the firm.
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
UBS Initiates Coverage of Bio-Rad Laboratories, Fulgent Genetics, Bio-Techne
The global financial services firm gave ratings of Buy, Neutral, and Buy to Bio-Rad, Fulgent, and Bio-Techne, respectively.